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a-Melanocyte-stimulating hormone inhibits neutrophil-indepen-
dent renal injury.
Background. We previously showed that a-melanocyte stimu-
lating hormone (a-MSH) decreases ischemia/reperfusion injury
even when started six hours after ischemia. a-MSH inhibits both
neutrophil accumulation and nitric oxide production. To deter-
mine the relative importance of a-MSH on the neutrophil path-
way, we examined the effects of a-MSH in injury models where
neutrophil effects are minimal or absent.
Methods. We studied the effects of a-MSH in (1) intercellular
adhesion molecule-1 (ICAM-1) knock-out and background mice
that were subjected to 40 minutes of ischemia and 24 hours
reperfusion, and (2) isolated kidneys that were subjected to in vivo
ischemia for 20 minutes and then perfused ex vivo for one hour
without neutrophils. To begin to search for direct tubule effects of
a-MSH, we studied the effect of a-MSH on nitric oxide (NO) in
endotoxin/interferon-g-treated mouse cortical tubule cells.
Results. ICAM-1 knock-out mice had 75% less neutrophil
infiltration than background mice after ischemia. Despite the
relative lack of neutrophils, a-MSH inhibited renal injury in
ICAM-1 knock-out mice. a-MSH also significantly preserved
GFR and tubular sodium reabsorption in the isolated perfused
ischemic kidney model. a-MSH and a nitric oxide inhibitor did not
exhibit synergy. Finally, a-MSH inhibited nitrite production by
20% in the mouse cortical tubule cells (MCT), similar to parallel
observations in a cultured mouse macrophage line (RAW cells).
Conclusions. We conclude that a-MSH decreases renal injury
when neutrophil effects are minimal or absent, indicating that
a-MSH inhibits neutrophil-independent pathways of renal injury.
The preservation of sodium absorption ex vivo and inhibition of
nitrite production in cultured MCT cells suggests that a-MSH
inhibits tubular injury by direct tubular effects.
Organ ischemia is the primary cause of stroke, myocar-
dial infarction, and acute renal failure, and increases the
risk of rejection following organ transplantation. While
prolonged ischemia causes anoxic cell death, additional
waves of injury initiated following sublethal injury are
caused in part by maladaptive inflammatory and cytotoxic
injury cascades activated during the reperfusion period.
Recent studies of renal ischemia-reperfusion injury have
focused on the roles of neutrophils and cytotoxic nitric
oxide. Following renal ischemia, neutrophils accumulate in
the outer stripe of outer medulla beginning four hours after
ischemia, which is coincident with histologic evidence of
ischemia [1–3]. While infiltrating neutrophils can remove
necrotic and apoptotic cells and hence is a passive response
to injury, many studies indicate that the neutrophils play a
pathogenic role. For example, neutrophils may plug the
ascending vasa recta in the outer stripe of the outer
medulla, and further impair oxygen supply to the proximal
straight tubule, the major site of injury in the clamp model
of renal injury [2]. Support for this pathogenic role comes
from studies where ischemic injury is partially inhibited by
neutrophil depletion in some [4, 5], but not all [6, 7],
studies. Ischemic renal injury is potentiated by infusion of
activated neutrophils [8, 9] and is decreased by blocking
antibodies or antisense oligonucleotides to intercellular
adhesion molecule-1 (ICAM-1) or P-selectin or mice lack-
ing ICAM-1 [10–14]. The amount of protection by neutro-
phil depletion/inhibition is more striking with shorter
ischemia times. However, cardiac and renal ischemia-
reperfusion injury can occur in the absence of neutrophils
[15, 16], suggesting other mechanisms of injury. Recent
studies have focused on maladaptive cytotoxic cascades
activated during reperfusion that liberate high concentra-
tions of cytotoxic nitric oxide (NO). Hypoxic/reperfusion
injury to isolated non-perfused proximal tubules can be
inhibited by blocking nitric oxide production [17]. The
inducible isoform of NO synthase (iNOS) is induced by
ischemia in proximal tubules. Blocking iNOS with antisense
oligonucleoides protects cultured proximal tubule cells
from hypoxic damage in vitro and against ischemic damage
in vivo [18]. In addition to being directly cytotoxic, the high
concentrations may also inhibit endothelial NO, with re-
sultant increased organ ischemia [19]. Taken together, the
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experimental evidence suggests that cytotoxic NO also
plays a pathogenic role in renal injury.
a-MSH is an anti-inflammatory cytokine that inhibits
both neutrophil and nitric oxide pathways. a-MSH inhibits
neutrophil infiltration by both direct and indirect mecha-
nisms: it inhibits the synthesis of neutrophil chemokine
interleukin (IL)-8 and neutrophil adhesion molecule
ICAM-1 [3, 20], and directly inhibits IL-8 stimulated neu-
trophil migration in vitro [20–22] via melanocortin a-MSH
receptors [23]. a-MSH also inhibits the induction of NO in
vivo and in vitro [20, 24, 25]. The ability of a-MSH to inhibit
both neutrophil and NO pathways suggested that a-MSH
might inhibit ischemia/reperfusion injury. Indeed, a-MSH
inhibited renal ischemia-reperfusion injury even when
started six hours after reperfusion [3]. a-MSH inhibited
both neutrophil infiltration, induction of mRNA for IL-8
and ICAM-1, and induction of iNOS enzyme and activity.
a-MSH was more effective in inhibiting renal damage after
ischemia than other agents that inhibit only one pathway.
The potential ability of a-MSH to inhibit a non-neutrophil
pathway is particularly interesting. Studies employing iso-
lated perfused hearts and kidneys have shown that cardiac
and renal ischemia-reperfusion injury can occur in the
absence of neutrophils [15, 16]. Furthermore, the role of
neutrophils in human acute renal failure is controversial.
Neutrophils are seen in human biopsy material, but not to
the extent as in the animal models [26]. However, renal
biopsies are generally not obtained early in the course of
acute renal failure, and special stains are required to detect
neutrophils [27]. Monoclonal antibodies to ICAM-1 had
only a small effect in post-transplant acute renal failure in
humans [28]. Thus, agents that inhibit both neutrophil-
dependent and neutrophil-independent pathways may be
useful as therapeutic agents.
In this study, we examined the effects of a-MSH on renal
ischemia/reperfusion injury in two injury models where
neutrophil infiltration is either less prominent (ICAM-1
knock-out mice) or absent (isolated kidney perfused in the
absence of neutrophils). Renal damage was assessed by
creatinine and by changes in renal histology in the in vivo
model, and by GFR and sodium absorption in the ex vivo
isolated perfused kidney model. We also examined the
effects of a-MSH on NO production in cultured mouse
cortical tubule (MCT) cells.
METHODS
Animals
Female C57BL/6J or ICAM-1 knock-out [B/6J-
ICAM(tm1BAY)] mice aged 7 to 8 weeks (20 to 22 g) were
purchased from Jackson Laboratories (Bar Harbor, ME,
USA). All animals had free access to water and food (4%
mouse-rat diet; Harlan Sprague-Dawley or low potassium
diet containing 50% of usual dietary potassium [29]). Rats
(275 to 300 g) were purchased from Sasco (Omaha, NE,
USA). Animal care followed the criteria of the University
of Texas Southwestern Medical Center and the University
of Colorado for the care and use of laboratory animals in
research.
Chemicals
a-MSH was purchased from Phoenix Pharmaceuticals,
Inc. (Mountain View, CA, USA). Sterile normal saline was
from Baxter Healthcare Corp. (Deerfield, IL, USA); Naph-
thol AS-D Chloroacetate Esterase Stain Kit (Kit # 91-C;
Sigma); Periodic Acid-Schiff (PAS) Kit (Kit # 395-8,
Sigma), and 10% formalin (Fisher); Albumin (fraction
V-Cohn bovine; Integren, Purchase, NY, USA); hydroxyl-
[methyl-14C]-inulin (Amersham); and Lw-nitro-L-arginine
(L-NNA, Sigma). All other chemicals were purchased from
Sigma Chemical Co.
Surgery and experimental protocol
Surgery was performed as described previously [3]. The
40 minute ischemia time was chosen to provide significant
renal injury that could be reversed by experimental agents.
The mice were anesthetized with an i.m. injection of 100
mg/kg ketamine, 10 mg/kg xylazine, and 1 mg/kg aceproma-
zine. The animals were placed on 39°C heating table to
maintain constant body temperature. Blood (100 ml) was
collected from the tail vein. Both renal pedicles were
cross-clamped for 40 minutes. a-MSH or vehicle was given
at the time of clamp release. After the clamps were
removed, 1 ml of prewarmed (37°C) normal saline was
instilled into the abdominal cavity. The abdomen was
closed, and the animals were placed in a 29°C incubator
overnight. At the time of sacrifice, blood was collected for
measurement of plasma creatinine. Both kidneys were
harvested for histological study or RNA. The animals were
divided into three groups: sham, ischemia/vehicle, and
ischemia/a-MSH. Sham-treated animals went through the
same surgical procedure as the other animals, including
dissection of the renal pedicle, however, renal clamps were
not applied. The vehicle and a-MSH treated animals
received vehicle (normal saline) or 25 mg a-MSH intrave-
nously during the ischemic period, and at 6 and 18 hours
post-perfusion. Creatinine was measured by an Beckman
creatinine autoanalyzer.
Histological examination
Formalin (10%)-fixed and paraffin-embedded kidney
specimens were stained with hematoxylin and eosin (H &
E; 2 mm), naphthol AS-D chloroacetate esterase (3 mm), or
periodic acid Schiff (PAS; 2 mm) stains. Histological
changes were evaluated by semiquantitative measurements
of neutrophil infiltration, tissue necrosis and erythrocyte
congestion as described previously [3].
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RNA extraction and Northern blot hybridization
Renal total RNA was purified using guanidinium thiocy-
anate-phenol-chloroform extraction [30]. Samples of total
RNA (20 mg) were fractionated via electrophoresis on
0.9% agarose-formaldehyde gel and transferred onto a
nylon membrane. The equality of RNA samples after
transfer to the membrane was substantiated by UV illumi-
nation of ethidium bromide. Membranes were fixed by
baking at 80°C, then prehybridized at 42°C in 50% form-
amide, 0.5% SDS and 53 Denhardt’s, 5 3 SSC, and 0.5
mg/ml salmon sperm DNA. The membranes were hybrid-
ized with [32P]dCTP-labeled cDNA clones. 0.5 to 2 kB
portions of mouse KC/IL-8 and ICAM-1 were generated by
PCR, and the products confirmed by automated sequenc-
ing. The hybridized membranes were washed twice in 0.1 3
SSC and 0.1% SDS at 50°C. Loading of RNA was normal-
ized by rehybridizing with GAPDH.
Isolated perfused ischemic rat kidney experiments
Kidneys were made ischemic in vivo, then perfused ex
vivo as described previously [16]. The ischemia time was
chosen to provide significant renal injury that could be
reversed by experimental agents. Briefly, after anesthesia,
the right renal artery was occluded for 20 minutes. The
right renal artery was cannulated and flushed with a
solution containing vehicle or 100 nM a-MSH, and the
entire kidney was transferred to a perfusion chamber for
perfusion with a pulsatile pump at a constant pressure of
100 mm Hg. After a 15-minute equilibrium period, three
urine collections and perfusion samples were obtained at 15
minute intervals. Samples were frozen within 60 minutes of
collection, and subsequently analyzed for [14C]-inulin and
sodium. The perfusate solution consisted of 150 ml of a
Krebs-Ringer bicarbonate buffer containing urea, [14C]-
inulin, albumin and vehicle, 100 nM a-MSH, or 100 nM
a-MSH and 10 mM L-NNA. The final composition of the
perfusion solution was (in mM) 140 Na, 5 K, 105 Cl, 25
bicarbonate, 1.2 ionized Ca, 1 Mg, 1 sulfate, 1 phosphate, 7
urea, 70 mg/ml albumin, and 5 glucose. Renal injury was
assessed by changes in glomerular filtration rate (GFR) and
tubular sodium reabsorption (TNa). Sodium was measured
with a model IL 343 flame photometer (Instrumentation
Laboratory, Lexington, MA, USA). Radioactivity of [14C]-
inulin was measured by a liquid scintillation counter.
Urinary clearances of [14C]-inulin and sodium were calcu-
lated from the urine and plasma concentration ratios.
Cell culture
Mouse cortical tubule (MCT) cells were grown in RPMI
1640 medium supplemented with penicillin, streptomycin,
and 10% heat-inactivated fetal bovine serum (Atlanta
Premium Select; Atlanta Biologicals, Norcross, GA, USA).
RAW 264.7 cells were maintained in Dulbecco’s modified
Eagle medium supplemented with 4.5 g/liter glucose, non-
essential amino acids, 4 mM L-glutamine, penicillin, strep-
tomycin, and 10% heat-inactivated fetal bovine serum.
MCT and RAW cells were seeded in 96 well microplates at
concentrations of 1.2 3 104 and 7.5 3 104 cells per 100 ml
per well. The cells were incubated for 30 hours at 37°C in
5% CO2/air. MCT cells were treated after 30 hours with
0.35 U/ml recombinant mIFN-g with or without 0.35 nM
a-MSH in an additional 100 ml complete-RPMI/well. The
RAW cells were treated after 30 hours with 10 ng/ml LPS
(E. coli 026:B6; Sigma) with or without 0.35 nM a-MSH in
an additional 100 ml complete D-MEM/well. The treated
cells were incubated for an additional 16 to 20 hours at
37°C. Nitrite concentrations were determined with Greiss
reagent using NaNO2 as a standard [30]. All assays were
performed using three to four replicates, and repeated in at
least four independent experiments.
Statistical analysis
All data were described as mean 6 SEM. Different
treatments were compared using ANOVA techniques
(completely randomized design) followed by Tukey’s test
for individual comparisons between group means. The null
hypothesis was rejected when P , 0.05.
RESULTS
Functional protection by a-MSH in ICAM-1 knock-out
mice
Forty minutes of renal ischemia caused severe injury; all
of the background C57BL/6J animals in the placebo group
died. All of the a-MSH treated background mice survived
with a mean plasma creatinine at 24 hours of 3.3 6 0.3
mg/dl. In contrast, all the placebo-treated ICAM-1 knock-
out animals survived, with a mean creatinine of 3.3 6 0.3
mg/dl. a-MSH significantly reduced the plasma creatinine
measured 24 hours after injury to 0.9 6 0.3 mg/dl. Thus, the
ICAM-1 knock-out mice survived a lethal amount of renal
injury, similar to the protection against a lessor amount of
ischemic injury reported by Kelley et al [10]. a-MSH
inhibited the decline in renal function in the ICAM-1
knock-out mice, and allowed the background mice to
survive.
The initial group of mice were fed normal rat/mouse
chow, which may have caused lethal hyperkalemia (not
measured). Therefore, the experiment was repeated in
animals fed a low potassium diet that contained about 50%
of the potassium content of the normal chow. Since this
modification allowed the placebo-treated background ani-
mals to survive (see below), all subsequent experiments
were conducted using this diet. Figure 1 shows the effect of
a-MSH in background and ICAM-1 knock-out mice sub-
jected to 40 minutes of ischemia with reperfusion for 24
hours. Under these conditions, the difference between the
vehicle-treated background and ICAM-1 knock-out ani-
mals was not statistically significant. a-MSH significantly
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inhibited renal injury in both the background (placebo,
3.2 6 0.2 mg/dl; a-MSH, 1.5 6 0.2 mg/dl) and ICAM-1
knock-out animals (placebo, 2.9 6 0.2 mg/dl; a-MSH, 0.7 6
0.2 mg/dl). a-MSH was significantly more effective in the
ICAM-1 knock-out animals (by ANOVA and Tukey mul-
tiple comparison test), with 103% reduction in creatinine in
ICAM-1 knock-out mice versus 59% reduction in back-
ground mice.
Histology
To determine if the functional changes were associated
with anatomical evidence of necrosis, we investigated his-
tologic changes at 24 hours post-ischemia. Figure 2 shows
typical histologic patterns seen in the four groups of
animals. Placebo-treated animals of either group showed
widespread necrosis of S3 proximal tubules in the outer
stripe of the outer medulla (Fig. 2 A, B). The placebo-
treated background animals showed extensive neutrophil
accumulation in the outer stripe, and erythrocyte conges-
tion in the inner stripe (Fig. 2A). In contrast, the placebo-
treated ICAM-1 knock-out animals had much less neutro-
phil accumulation in the outer stripe (Fig. 2B). a-MSH had
only slight effect in background mice (Fig. 2C). In contrast,
a-MSH had a dramatic protective effect on renal histology
in the ICAM-1 knock-out mice (Fig. 2D). There were only
a few casts, patchy congestion, and minimal necrosis.
The histologic changes were measured using semiquan-
titative scales (0 to 31) for outer stripe tissue necrosis and
inner stripe erythrocyte congestion (Fig. 3), and quantita-
tive counts of the number of neutrophils in the outer stripe
of the outer medulla (Fig. 4). a-MSH decreased outer
stripe tissue necrosis in both background and ICAM-1
knock-out mice, but had a more impressive effect in the
ICAM-1 knock-out mice. a-MSH inhibited inner stripe
erythrocyte congestion in both sets of animals. The
ICAM-1 knock-out mice had significantly less neutrophil
accumulation than the background mice (background,
346 6 39 vs. ICAM-1 knock-out, 82 6 13 neutrophils per
mm2). a-MSH significantly reduced neutrophil infiltration
in both the background and ICAM-1 knock-out animals
(background, 210 6 36; ICAM-1 knock-out, 12 6 10
neutrophils per mm2), but had a more pronounced effect in
the ICAM-1 knock-out animals (85% reduction in ICAM-1
knock-out mice vs. 39% reduction in background animals).
The ICAM-1 mice had detectable neutrophil accumula-
tion in the kidney, perhaps in response to tissue injury
rather than causing it. Since fewer neutrophils accumulate
at shorter ischemia times, we tried less ischemia time in the
ICAM-1 knock-out mice. While we did get less ischemic
damage, we still found neutrophil accumulation in the
outer medulla (data not shown).
RNA blot analysis of ICAM-1 mRNA
To demonstrate that ICAM-1 was absent in the knock-
out mice, we performed RNA blotting for ICAM-1 mRNA.
Figure 5 shows that ICAM-1 mRNA was absent, as ex-
pected, in the ICAM-1 knock-out animals. Ischemia in-
creased ICAM-1 mRNA abundance in the background
animals, and a-MSH inhibited induction of ICAM-1. These
changes are similar to what we found in Balb/c mice at 24
hours [3].
Effects of a-MSH in the isolated perfused kidney
We performed additional experiments using an isolated
perfused kidney model where neutrophils could be com-
pletely eliminated during the reperfusion period. Rat kid-
neys were made ischemic in situ for 20 minutes, flushed
with buffer, and perfused ex vivo in an isolated kidney
perfusion system. The flush and perfusion solutions con-
tained vehicle or a-MSH (100 nM). a-MSH caused a slight
but statistically nonsignificant decrease in perfusion flow to
the ischemic kidneys (control, 34 6 3 ml/min vs. a-MSH,
29 6 2 ml/min). Figure 6 shows the effects of a-MSH on the
function of the ischemic kidneys studied ex vivo. The
shaded areas correspond to glomerular filtration rate
(GFR) and tubular sodium absorption (TNa,, a marker of
proximal tubule function) previously found in non-ischemic
kidneys studied ex vivo [9, 16]. As expected, the vehicle-
treated ischemic kidneys (open circles) had significantly
lower GFR and tubular sodium absorption than non-
ischemic kidneys, with recovery of both GFR and sodium
absorption over time. Compared with vehicle, a-MSH
addition significantly improved both glomerular (GFR) and
tubular (TNa) function at 30, 45, and 60 minutes of reper-
fusion (closed circles). In non-ischemic kidneys, a-MSH
had no effect on GFR or tubular sodium absorption (data
not shown).
To evaluate the contribution of NO in mediating the
neutrophil independent protective effects of a-MSH, we
studied the effect of 100 nM a-MSH and 10 mM L-NNA.
Fig. 1. Effect of a-MSH in background and ICAM-1 knock-out mice.
Mice were subjected to 40 minutes ischemia, received vehicle or 25 mg
a-MSH just before clamp release, placed on a low potassium diet, and
sacrificed after 24 hours. Data shown as mean 6 standard error. *P ,
0.05.
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This concentration of L-NNA has been shown previously to
partially inhibit ischemia/reperfusion damage in the ab-
sence of neutrophils (Fig. 6; open triangles) [16]. We found
that addition of L-NNA and a-MSH together (open dia-
monds) had similar effects as a-MSH alone (closed circles).
There was no evidence of additivity.
Effect of a-MSH on nitrite production
Since the lack of additivity between L-NNA and a-MSH
in the isolated perfused kidney preparation suggested that
a-MSH might inhibit renal NO, we tested this possibility in
MCT cells. Incubation with 0.35 nM a-MSH for 16 hours
decreased IFN-g-stimulated NO production in MCT cells
by 19.7 6 2.4% (Fig. 7). The degree of inhibition was not
statistically different than that observed in parallel experi-
ments in cultured mouse macrophages (RAW cells).
DISCUSSION
a-MSH inhibits both inflammatory (neutrophil) and
cytotoxic (nitric oxide) pathways in renal ischemia. The
present studies were designed to assess the role of neutro-
phil-independent pathways both in an in vivo model
(ICAM-1 knock-out) and an ex vivo model (isolated isch-
emic kidney perfused without neutrophils). The major new
findings in this paper are: (1) a-MSH is more effective in
ICAM-1 knock-out mice than in the background strain, (2)
a-MSH inhibits renal injury in the isolated kidney perfused
without neutrophils, (3) a-MSH has direct tubule effects,
and (4) a-MSH is less effective in C57BL/6J than Balb/c
mice. Taken together, the evidence suggests that a-MSH
can inhibit renal injury without neutrophils present, per-
haps via a direct tubular effect. These findings are discussed
below.
a-MSH is more effective in ICAM-1 knock-out mice than
in the background strain
Previous studies by Kelley et al and Rabb et al have
shown that interruption of ICAM-1 either by genetic
knock-out or blocking antibody made mice less sensitive to
renal ischemia [10, 11, 13]. Since the degree of protection
was more pronounced at the shorter ischemia times, it is
Fig. 2. Typical renal histology of outer stripe of outer medulla. Sections stained with Ledar stain for neutrophils (pink, arrowheads). (A) Background
mouse, vehicle. (B) ICAM-1 knock-out mouse, vehicle. (C) Background mouse, a-MSH. (D) ICAM-1 knock-out mouse, a-MSH.
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suspected that ICAM-1 dependent and hence neutrophil-
dependent injury pathways are more important at shorter
ischemia times [27]. We used a more severe insult (40 min
clamp) to obtain both neutrophil-dependent and neutro-
phil-independent mechanisms of injury. Even with this
severe injury, ICAM-1 knock-out animals were less sensi-
tive to ischemia, as assessed by survival on a normal mouse
diet (100% survival in ICAM-1 knock-out mice vs. 100%
death in background mice). A similar but smaller survival
advantage in ICAM-1 knock-out mice has been noted using
32 minutes of ischemia (50% of the background animals
died within 72 hours, whereas all of the ICAM-1 knock-out
mice survived [10]). On a low potassium diet, we found a
small numerical difference in serum creatinine at 24 hours
(Fig. 1), although it was not statistically significant. While
Kelly et al previously demonstrated a dramatic protective
effect in the ICAM-1 knock-out mice using 32 minutes of
ischemia, their background animals had a creatinine at 1.4
mg% at 24 hours versus the 2.9 mg% in the present study
that employed 40 minutes ischemia. Nevertheless, the
ICAM-1 knock-out mice had 76% less neutrophil infiltra-
tion in response to ischemia than the background mice (82
neutrophils per mm2 in ICAM-1 knock-out mice vs. 346 in
background mice). Thus, the ICAM-1 knock-out mice were
modestly protected from ischemic damage, indicating renal
ischemic/reperfusion injury is mediated by both neutrophil
and non-neutrophil injury cascades.
We previously found that a-MSH inhibited renal isch-
emic injury in Balb/c mice [3]. In this study, a-MSH
inhibited renal injury following 40 minutes of bilateral
ischemia in both background and ICAM-1 knock-out mice
in normal and low potassium diets (Fig. 1). However, the
degree of protection was larger in the ICAM-1 knock-out
mice, where a-MSH inhibited the rise in plasma creatinine
at 24 hours post-ischemia. The degree of protection was
collaborated by the renal histological changes (Fig. 2).
Whereas a-MSH was not very effective in the background
animals (see below), a-MSH reduced renal histological
damage to near baseline values in the ICAM-1 knock-out
mice (Fig. 3). a-MSH also inhibited neutrophil infiltration
in the ICAM-1 knock-out animals, to levels similar to the
sham animals. Taken together, the results demonstrate that
a-MSH was more effective in preserving renal function and
cellular viability in the ICAM-1 knock-out animals than the
background animals. The degree of protection to moder-
ately severe renal ischemia/reperfusion injury has been
seen previously by a-MSH in Balb/c mice and P-selectin
inhibitors. However, the P-selectin inhibitor had to be given
Fig. 3. Effect of a-MSH on semiquantitative
histologic changes (tissue necrosis and
erythrocyte congestion). The Methods section
contains a description of the methodology.
Fig. 4. Effect of a-MSH on the number of neutrophils in the outer stripe
of the outer medulla. Neutrophil counts expressed as mean 6 1 standard
error. Symbols are: (f) vehicle; (u) a-MSH. *P , 0.05 versus vehicle.
**P , 0.05 versus background.
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before renal ischemia, whereas a-MSH could be given up
to three to six hours after ischemia [3, 14]. The ICAM-1
knock-out animals had 76% less neutrophil infiltration and
a-MSH still greatly inhibited renal damage, suggesting that
a-MSH must also work via neutrophil-independent path-
ways. However, it is also possible that the 26% remaining
neutrophils were sufficient to cause renal injury, and that
a-MSH protected the kidney by inhibiting accumulation of
the these neutrophils. To test if some effects of a-MSH are
independent of neutrophils required a different experimen-
tal approach.
a-MSH inhibits renal injury in the isolated kidney
perfused without neutrophils
Preventing neutrophil infiltration is very difficult in ex-
perimental animals. Neutrophil depletion with anti-neutro-
phil serum is protective, but only if neutrophils were
depleted to extremely low levels. Since neutrophil depen-
dent injury is more prevalent at low ischemia times [27], we
tried shorter ischemia times. As expected, we observed less
ischemic damage, however, we were unable to eliminate
neutrophil infiltration in the ICAM-1 knock-out mice.
Therefore, additional studies were performed using a dif-
ferent experimental system (isolated perfused kidney prep-
aration) where neutrophils could be eliminated during the
reperfusion period. Kidneys were made ischemic in vivo
then transferred to an ex vivo perfusion system where they
could be perfused without neutrophils. Even under these
conditions, treatment with a-MSH resulted in marked
protection of both glomerular and tubular functions;
a-MSH returned GFR and tubular function towards nor-
mal more rapidly than in untreated kidneys. The free
Fig. 5. Outer medullary ICAM-1 mRNA by RNA blotting. RNA (20 mg/lane) was electrophoresed and blotted for ICAM-1. Each lane represents RNA
from a single animal. Blot shown is representative of two similar experiments.
Fig. 6. Effect of a-MSH on kidney function.
(A) Glomerular filtration rate (GFR). (B)
Tubular sodium reabsorption (TNa) following 20
minutes of ischemia in vivo and perfusion
without neutrophils by the isolated kidney
technique. The shaded area represents normal
values for non-ischemic kidneys. Data from L-
NNA were obtained from [16]. Symbols are:
(E) vehicle; (F) a-MSH; () L-NNA; (l) L-
NNA 1 a-MSH. N 5 5 experiments for vehicle
and a-MSH studies, and N 5 3 for a-MSH and
L-NNA studies.
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radical scavengers DMTU, DMSO, and xanthine oxidase
inhibitors have also proven to be more effective in protect-
ing isolated perfused kidneys from ischemia/reperfusion
injury in the absence of neutrophils [31, 32]. a-MSH was as
effective as each of these agents in protecting kidneys from
ischemia. Kainz et al have reported in abstract form a
similar study employing ex vivo ischemia, where kidneys
were perfused for one hour ex vivo, made ischemic for 20
minutes, then reperfused without neutrophils. a-MSH also
inhibited renal injury under these conditions [33]. Thus,
a-MSH inhibits renal ischemia/reperfusion damage in the
absence of neutrophils, indicating that a-MSH must act on
other injury cascades. Since a-MSH was only given to the
ischemic kidney and not infused systemically, the protective
effects of a-MSH do not require a systemic action (hemo-
dynamic, anti-inflammatory, or otherwise), but are largely
mediated by the direct action of a-MSH on the kidney.
Whether a-MSH has additional beneficial systemic actions
during renal ischemia is unknown.
We previously found that a-MSH inhibited induction of
inducible NO synthase (iNOS) in murine macrophages in
vitro, endotoxin-induced liver injury, and ischemia-induced
renal injury [3, 20, 25]. a-MSH inhibited production of high
concentrations of NO in the outer medulla during ischemia
[3]. High concentrations of NO produced by proximal
tubules are thought to be a pathogenically important cause
of renal injury, since inhibition of NO decreases injury in
vitro and in vivo [17, 18]. We evaluated the potential role of
NO in mediating the neutrophil-independent effects of
a-MSH using the NO inhibitor L-NNA. a-MSH was more
effective than L-NNA alone, suggesting that a-MSH has
effects other than inhibition of NO. We also found that
a-MSH and L-NNA together were about as effective as
a-MSH alone. The lack of additivity between a-MSH and a
NO inhibitor suggests that the two agents share common
mechanisms of action. The identity of the NO- and neutro-
phil-independent pathway(s) are unknown, but worthy of
further study.
a-MSH has direct tubule effects
The isolated perfused kidney studies cannot conclusively
provide a mechanism. a-MSH did not increase the perfu-
sion flow rate, suggesting that it does not act as a vasodi-
lator. Therefore, the effect of a-MSH to preserve sodium
excretion suggests that a-MSH might have a direct effect
on the proximal tubule. a-MSH also inhibits injury to the
S3 proximal straight tubule in the relative absence of
neutrophils (Fig. 2), consistent with a local effect of a-MSH
in the vicinity of the outer medulla. We previously showed
that a-MSH inhibited production of high concentrations of
NO in the outer medulla during ischemia [3]. Since the
isolated kidney preparation experiments suggested that
a-MSH may act in part via inhibition of NO, we tested the
effects of a-MSH on cytokine-induced iNOS in MCT cells,
a cell line derived from proximal tubules. a-MSH inhibited
cytokine-stimulated NO production (Fig. 7). This concen-
tration of a-MSH is slightly below the reported EC50 for all
melanocortin receptors (1 nM) (discussed in [25]), indicat-
ing that the MCT cells express a functional melanocortin
receptor. We have recently produced a polyclonal antibody
to the MC-1 melanocortin receptor that stains human and
mouse neutrophils in a plasma membrane pattern [23].
This antibody also detects MC1 in MCT cells by protein
blotting, suggesting that a-MSH may work in part via
stimulation of MC1 a-MSH receptors. It is not known if
this receptor is expressed on the apical or basolateral
membrane.
While the signals responsible for increasing iNOS in vivo
are unknown, ischemia increases the renal production of
pro-inflammatory cytokines and chemokines (including
IL-1, TNF-a, IL-8, MCP, etc.) [3, 10, 34], which may
subsequently induce expression of iNOS. Taken together,
the data indicate that a-MSH has at least one direct tubular
action that is independent of its actions on neutrophils.
Whether a-MSH acts at other tubular or vascular sites in
the kidney is unknown. We have detected expression of
MC-1 on the apical membrane of collecting ducts from
cortex to inner medulla [23]; however, the physiological
function of this receptor is unknown.
a-MSH is not effective in the C57BL/6J background mice
We previously found that a-MSH dramatically reduced
renal reperfusion injury and neutrophil infiltration in
Balb/c mice. a-MSH restored both to levels detected in
sham-operated animals. In those mice, a-MSH inhibited
the rise in renal RNA abundance for the neutrophil
Fig. 7. Effect of a-MSH on LPS and IFN-g stimulated nitrite production
in mouse cortical tubule (MCT) cells and RAW 264.7 cells. Symbols are:
(M) control; (f) a-MSH. *P , 0.05 versus control (no a-MSH).
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chemokine IL-8 and ICAM-1 [3]. In contrast, the C57BL/6J
mice are more sensitive to renal ischemia, and a-MSH only
inhibited renal injury by 53% (as judged by changes in
creatinine at 24 hr) and neutrophil infiltration by 39%.
a-MSH inhibited the ischemia-induced increase in ICAM-1
as in Balb/c mice. Mice strains vary in their degree of
susceptibility to cerebral ischemia. Yang et al found that
the C57BL/6 strain was the most susceptible to cerebral
ischemia following bilateral common carotid occlusion
among seven host strains [35]. Survival correlated with the
degree of anatomical anastomosis between carotid and
basilar arteries. It is not known if there are anatomical
differences in renal vasculature between C57BL/6 and
Balb/c mice. However, the C57BL/6 and Balb/c mice strains
have immunological differences that cause susceptibility to
certain diseases. For example, most clones from Leishma-
nia major resistant C57BL/6 mice produce Th1 cytokines
(IFN-g), whereas T-cells from L. major susceptible Balb/c
mice produce Th2-dominant responses (that is, IL-4) [36,
37]. In contrast, C57BL/6 mice are more susceptible to C.
parvum/LPS-induced liver injury than Balb/c mice [38].
Blockade of IL-12 or IFN-g abrogates injury in C57BL/6
mice, while IL-12 induces C. parvum/LPS-induced injury in
resistant Balb/c mice [38]. Thus, subtle differences in
anatomical arrangement or cytokine responsiveness be-
tween the strains might account for differences in suscep-
tibility to ischemia and effectiveness of a-MSH. Elucida-
tion of these differences may allow further insight into the
mechanisms of ischemia and actions of a-MSH.
Physiologic significance
Animal models of ischemic injury suggest the involve-
ment of multiple injury cascades involving neutrophils,
inflammation, nitric oxide, superoxide, calcium, etc. In
contrast, the mechanisms of human acute renal failure are
poorly understood largely because human acute renal
failure is multi-factorial, there are only a few reported
series of human biopsy material, and biopsies are generally
not obtained at the time of initiation of acute renal failure.
The role of neutrophils in human acute renal failure is
particularly controversial. The reported series do show
some neutrophils, but not to the extent seen in the rat and
mouse models of renal ischemia/reperfusion injury. Never-
theless, our studies show that a-MSH decreases renal injury
in the relative and complete absence of neutrophils, indi-
cating that a-MSH works on neutrophil-independent path-
ways. Given the uncertainty of the mechanisms of human
acute renal failure, it is likely that an agent that inhibits on
several injury cascades is more likely to be therapeutically
important than one that only inhibits a single cascade. Since
a-MSH works on both neutrophil-dependent and neutro-
phil-independent pathways, it may be more effective than
agents that only inhibit neutrophil events. The preservation
of sodium absorption ex vivo and inhibition of NO produc-
tion in cultured MCT cells suggests that a-MSH may work,
in part, via direct tubular effects.
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APPENDIX
Abbreviations used in this article are: a-MSH, a-melanocyte-stimulat-
ing hormone; GFR, glomerular filtration rate; H & E, hematoxylin and
eosin; ICAM-1, intercellular adhesion molecule-1; IFN-g, interferon-g;
IL, interleukin; iNOS, inducible nitric oxide synthase; L-NNA, Lv-nitro-
L-arginine; LPS, lipopolysaccharide; MCT, mouse corticle tubule; NO,
nitric oxide; PBS, phosphate buffered saline; TNa, tubular sodium reab-
sorption; TNF-a, tumor necrosis factor-a.
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